Skip to content

MiniMed Group MMED Pumps — Net Sales

Other product segments

CGM
$390M+18.2%
Consumables
$244M+14.6%

Similar metrics at other companies

Dover logo
DOVPumps & Process Solutions — Revenue
$537.81M+9.0%
Medtronic logo
MDTDiabetes Group — Net Sales
$838M+15.1%
Abbott logo
ABTMedical Devices — Net Sales
$5.54B+13.2%
Medtronic logo
MDTOther Operating Segments, Including Diabetes — Net Sales
$811.75M+12.3%
Mirum Pharmaceuticals, Inc. logo
MIRMProduct sales, net — Product sales, net
$159.88M+43.3%
Abbott logo
ABTDiagnostic Products — Net Sales
$2.18B+6.1%

Other financials

Income statement

See full
Revenue$790.0M+15.0%
Gross profit$362.0M-8.4%
Operating income-$100.0M-576%
Net income-$119.0M-1,090%
EPS (diluted)-$0.47-1,075%

Balance sheet

See full
Cash & equivalents$10.0M0.0%
Total debt$61.0M
Total equity$3.5B-0.7%
Total assets$4.3B

Cash flow

See full
Operating cash flow-$27.0M-147%
CapEx$167.0M+22.8%
Free cash flow-$194.0M-146%

Valuation

See full
Market cap$4.15B
Enterprise value$4.2B

Returns & leverage

See full
Return on equity-4.3%
Debt / equity
Current ratio1.6×

Where this comes from

Reported directly by MiniMed Group in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: MiniMed Group ’s 10-Q, filed April 17, 2026, on SEC EDGAR. View the filing →

Ask your AI about MiniMed Group 's pumps — net sales.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MiniMed Group 's pumps — net sales?
MiniMed Group (MMED) reported pumps — net sales of $151M in Q1 2026.
What does pumps — net sales mean?
This metric represents the total revenue generated from the sale of insulin pump devices and associated hardware components within the diabetes management segment. It reflects the company's market penetration and demand for its core medical device technology used by patients for automated insulin delivery. Growth in this figure indicates successful adoption of the company's primary therapeutic hardware solutions.